The Novo Nordisk Foundation committed 5.5 billion Danish kroner (about $857 million) to extend funding for the BioInnovation Institute from 2026 through 2035. The pledge will expand the institute’s support for early-stage life‑science and deep‑tech ventures and underwrite company formation and founder training across Denmark and potentially other European markets. The commitment addresses Europe’s persistent gap in commercialization capital and experienced entrepreneurial talent, aiming to convert academic discoveries into scalable companies. The foundation spun out the institute five years ago; the new funding materially increases its capacity to run incubators, provide early non‑dilutive capital, and scale mentorship networks. Sources: Novo Nordisk Foundation announcements and STAT reporting.